What are the precautions for Rimegepant orally disintegrating tablets?

In clinical studies of Rimegepant orally disintegrating tablets (Rimegepant) in the treatment of migraine, warnings and precautions such as allergic reactions, hypertension, and Raynaud's phenomenon have emerged. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Allergic reactions: including difficulty breathing and rash. Anaphylaxis can occur within days of administration, and delayed severe allergic reactions have occurred. If an allergic reaction occurs, discontinue Remedipam orally disintegrating tablets and initiate appropriate treatment.

2. Hypertension: It has been reported that the development of hypertension and the worsening of pre-existing hypertension may occur after the use of CGRP antagonists (including Remegipan orally disintegrating tablets) in the post-marketing environment. Some patients with new-onset hypertension have risk factors for hypertension. Some cases require the initiation of medication for high blood pressure, and some require hospitalization. Hypertension may occur at any time during treatment but is most reported within 7 days of starting treatment. Monitor patients receiving Remedigelpan orally disintegrating tablets for new onset of hypertension or worsening of pre-existing hypertension and consider the need to discontinue Remedigipan orally disintegrating tablets if evaluation fails to identify an alternative cause or blood pressure control is inadequate.

3. Raynaud's phenomenon: It has been reported that Raynaud's phenomenon and the recurrence or exacerbation of the original Raynaud's phenomenon occurred in the post-marketing environment after the use of CGRP antagonists (including Remedypan orally disintegrating tablets) . In reported cases using small molecule CGRP antagonists, symptoms developed an average of 1.5 days after administration. Many cases report serious consequences, including hospitalization and disability, often associated with debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in symptom resolution.

If signs or symptoms of Raynaud's phenomenon occur, use of Remedipam orally disintegrating tablets should be discontinued and if symptoms are not relieved, the patient should be evaluated by a healthcare provider. Patients with a history of Raynaud's phenomenon should be monitored and informed of the possibility of worsening or recurrence of signs and symptoms.

Reference materials:https://en.wikipedia.org/wiki/Rimegepant